Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Canadian Biotech

*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing…
Forget-Me-Not Whether you believe in the metaphysical or not, there’s no denying the achievements of science. In particular, biotechnology has uncovered significant advancements in the field of medicine. For context,…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research…
Xphyto Therapeutics (XPHY.C) diagnostic partner, 3a-Diagnostics GmbH, is getting onboard with the latest rush to develop a COVID-19 diagnostic kit, using reverse transcription polymerase chain reaction (RT-PCR) technology, which…
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in Well Health Technologies (WELL.T)…
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions….